Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Cash Flow (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Net Cash Flow data on record, last reported at -$2.8 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 188.7% year-over-year to -$2.8 million; the TTM value through Sep 2025 reached $513000.0, up 366.36%, while the annual FY2024 figure was -$1.2 million, 71.13% up from the prior year.
  • Net Cash Flow reached -$2.8 million in Q3 2025 per NWBO's latest filing, down from $5.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $10.9 million in Q4 2021 and bottomed at -$9.1 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$559105.3, with a median of -$560000.0 recorded in 2024.
  • Peak YoY movement for Net Cash Flow: surged 2662.04% in 2023, then tumbled 5700.0% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $10.9 million in 2021, then tumbled by 96.85% to $342000.0 in 2022, then tumbled by 965.79% to -$3.0 million in 2023, then crashed by 45.8% to -$4.3 million in 2024, then skyrocketed by 34.03% to -$2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.8 million in Q3 2025, $5.5 million in Q2 2025, and $2.2 million in Q1 2025.